KB-1265

Utomilumab

Background

Utomilumab(PF-05082566), is a recombinant IgG2 lambda, humanized monoclonal antibody produced in CHO cell culture, which binds specifically to 4-1BB(CD137), a receptor protein found in many immune cells, such as T-cells and NK cells. And when Utomilumab binds to 4-1BB, it has been observed to stimulate and increase the number of immune cells.

Specifications

Catalog Number:
KB-1265
Cell Line Name:
Utomilumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CD137
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip P. Patel, Leslie Popplewell, et al. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clin Cancer Res. CCR-19-2973 Published June 2020.
Please enable JavaScript in your browser to complete this form.